CellSource Co.,Ltd. Logo

CellSource Co.,Ltd.

Processes patient-derived stem cells and PRP for regenerative therapies at medical facilities.

4880 | T

Overview

Corporate Details

ISIN(s):
JP3423580004
LEI:
Country:
Japan
Address:
渋谷区渋谷一丁目23番21号
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

CellSource Co., Ltd. is a biotechnology company specializing in regenerative medicine. The company's core operation involves providing contract processing and storage services for tissues and cells to medical institutions. Its key services include the extraction of adipose-derived stem cells and the preparation of platelet-rich plasma (PRP) from patient-derived samples. By offering these specialized processing services, CellSource enables partner medical facilities to provide advanced regenerative therapies. The company's operations are primarily centered on its regenerative medicine-related business, and it also engages in a consumer-focused business segment.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-07-14 08:30
Board/Management Information
臨時報告書
Japanese 20.3 KB
2025-06-30 10:09
Share Issue/Capital Change
訂正臨時報告書
Japanese 30.7 KB
2025-06-12 08:36
Registration Form
確認書
Japanese 8.7 KB
2025-06-12 08:35
Interim Report
半期報告書-第10期(2024/11/01-2025/10/31)
Japanese 203.7 KB
2025-06-12 08:33
Share Issue/Capital Change
臨時報告書
Japanese 30.6 KB
2025-01-31 07:37
Governance Information
内部統制報告書-第9期(2023/11/01-2024/10/31)
Japanese 22.6 KB
2025-01-31 07:36
Registration Form
確認書
Japanese 8.7 KB
2025-01-31 07:35
Registration Form
有価証券報告書-第9期(2023/11/01-2024/10/31)
Japanese 1.0 MB
2025-01-31 07:32
Post-Annual General Meeting Information
臨時報告書
Japanese 24.9 KB
2024-10-31 07:06
Board/Management Information
臨時報告書
Japanese 19.3 KB
2024-06-13 08:07
Report Publication Announcement
確認書
Japanese 8.7 KB
2024-06-13 08:05
Quarterly Report
四半期報告書-第9期第2四半期(2024/02/01-2024/04/30)
Japanese 212.9 KB
2024-03-11 07:04
Report Publication Announcement
確認書
Japanese 8.8 KB
2024-03-11 07:03
Quarterly Report
四半期報告書-第9期第1四半期(2023/11/01-2024/01/31)
Japanese 162.2 KB
2024-01-25 08:35
Governance Information
内部統制報告書-第8期(2022/11/01-2023/10/31)
Japanese 22.9 KB

Automate Your Workflow. Get a real-time feed of all CellSource Co.,Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for CellSource Co.,Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for CellSource Co.,Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Alpha Cognition Inc. Logo
Develops and commercializes novel treatments for neurodegenerative diseases like Alzheimer's and ALS.
United States of America ACOG
Alteogen Inc. Logo
Biotech firm developing next-gen ADCs and biobetters with proprietary platform technologies.
South Korea 196170
ALTERITY THERAPEUTICS LTD Logo
Developing therapies for Parkinsonian disorders and MSA by inhibiting protein aggregation.
United States of America ATHE
Alto Neuroscience, Inc. Logo
Developing precision medicines for depression and schizophrenia using a brain biomarker platform.
United States of America ANRO
ALUMIS INC. Logo
Develops targeted oral therapies for immune-mediated diseases using precision immunology.
United States of America ALMS
Alvotech Logo
Develops and manufactures affordable biosimilar medicines for patients worldwide.
United States of America ALVO
Alvotech Holdings S.A Logo
Develops and manufactures affordable biosimilar medicines for global patient access.
Luxembourg ALVO
ALX ONCOLOGY HOLDINGS INC Logo
Clinical-stage firm developing CD47 inhibitors for hematologic and solid tumors.
United States of America ALXO
Alzamend Neuro, Inc. Logo
Developing lithium & vaccine therapies for neurodegenerative & psychiatric disorders.
United States of America ALZN
Alzinova AB Logo
Developing targeted immunotherapies, including a vaccine, for Alzheimer's disease.
Sweden ALZ

Talk to a Data Expert

Have a question? We'll get back to you promptly.